An Open-label, Uncontrolled 4-week Study to Assess the Safety, Efficacy and Pharmacokinetics of Allegra (Dry Syrup Formulation) 15 mg or 30 mg Twice Daily in Pediatric Patients With Perennial Allergic Rhinitis
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Fexofenadine (Primary)
- Indications Perennial allergic rhinitis
- Focus Adverse reactions
- Sponsors Sanofi
Most Recent Events
- 13 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Dec 2010 New trial record